Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Aflibercept on Treatment of Age-related Macular Degeneration
IRCT20150303021315N14Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of aflibercept in exudative macular degeneration, sponsored by CinnaGen. Started Jul 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on IRCT20150303021315N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N14.